NasdaqGS:JAZZPharmaceuticals
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization?
In recent days, Boehringer Ingelheim announced a clinical collaboration with Jazz Pharmaceuticals to test a combination of zongertinib and Jazz’s bispecific HER2 antibody zanidatamab in a Phase 1b cohort for HER2-positive breast cancer, while Jazz also sold an FDA priority review voucher linked to its brain cancer drug Modeyso for US$200,000,000.
These moves highlight Jazz’s push to monetise regulatory assets and deepen its oncology footprint through dual HER2-targeted approaches that could...